King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
07:09
Chronicle - Superliga | The red-blues are paler than a newly promoted team
06:59
Oana Gheorghiu, message for politicians eight years after the protest on August 10: "The day will come when you will pay. Even if justice does not succeed, the people will send you exactly where you belong."
23:05
The only anti-war party in Russia has been excluded from the electoral race.
23:00
Over 1,200 Palestinians have been killed in Gaza since the ceasefire with Israel came into effect in October 2025. UN experts warn of the ongoing genocide.
22:55
The Alba Iulia Court of Appeal rejected the proposal for the preventive arrest of prosecutor Radu George Bucurică, accused of crimes related to the illegal possession and use of a lethal firearm.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
